Page 206 - அமெரிக்கன் கல்லூரி ஆஃப் மகப்பேறியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article MINNEAPOLIS, April 6, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc.  The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.  The Asuragen acquisition adds a leading portfolio of best-in-class molecular diagnostic and research products, including genetic screening and oncology testing kits, molecular controls, a Good Manufacturing Practice (GMP)-compliant 50,000 square foot manufacturing facility and a CLIA-certified laboratory, plus a team with deep expertise navigating products through the global diagnostic regulatory environment.  Bio-Techne sees multiple growth synergies as a result of this acquisition, including capabilities in productizing lab-developed tests and commercializing innovative molecular products for broader market adoption.  Bio

David clairExchange commissionPrnewswire bio techne corporationAmerican college of obstetriciansCorporate developmentAsuragen incBio techne corporationTechne corporationGood manufacturing practiceAmerican collegeLooking statementsPrivate securities litigation reformSenior directorInvestor relationsடேவிட் கிளேர்பரிமாற்றம் தரகு